Skip to main content
TipRanks
Go Ultimate75% OFF

Compare ALK-abello (4AJ0) vs. Competitors

2 Followers

Comparison Results

Comparison results
NamePriceMarket CapP/E RatioYearly GainAnalyst ConsensusAnalyst Price TargetCompareTop Analysts' Price TargetSmart ScoreFollow
DE:4AJ0ALK-abelloEUR 32.44EUR 7.30B38.703.71%―Unlock the DE:4AJ0 analyst price target with TipRanks PremiumDE:4AJ0Unlock the DE:4AJ0 top-analyst price target with TipRanks Premium
AKBLFALK-abello$35.88$8.00B38.70-1.37%―Unlock the AKBLF analyst price target with TipRanks PremiumDE:4AJ0 vs AKBLFUnlock the AKBLF top-analyst price target with TipRanks Premium
INOInovio Pharmaceuticals$1.71$320.29M-2.15-3.93%Strong BuyUnlock the INO analyst price target with TipRanks PremiumDE:4AJ0 vs INOUnlock the INO top-analyst price target with TipRanks Premium
ACRSAclaris Therapeutics$3.50$555.14M-6.0342.28%Strong BuyUnlock the ACRS analyst price target with TipRanks PremiumDE:4AJ0 vs ACRSUnlock the ACRS top-analyst price target with TipRanks Premium
EBSEmergent Biosolutions$5.15$264.79M-1.02-47.93%HoldUnlock the EBS analyst price target with TipRanks PremiumDE:4AJ0 vs EBSUnlock the EBS top-analyst price target with TipRanks Premium
NVSNovartis$151.22$276.08B29.0218.78%Moderate BuyUnlock the NVS analyst price target with TipRanks PremiumDE:4AJ0 vs NVSUnlock the NVS top-analyst price target with TipRanks Premium
BMYBristol-Myers Squibb$58.34$119.25B12.9127.41%Moderate BuyUnlock the BMY analyst price target with TipRanks PremiumDE:4AJ0 vs BMYUnlock the BMY top-analyst price target with TipRanks Premium

Performance Comparison

-100%-50%0%50%100%150%200%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Performance comparison by fund
TickerCompany NamePriceChange% Change
DE:4AJ0ALK-abello32.440.983.12%
AKBLFALK-abello35.880.170.49%
INOInovio Pharmaceuticals1.71-0.02-1.16%
ACRSAclaris Therapeutics3.501.0945.23%
EBSEmergent Biosolutions5.15-3.93-43.28%
NVSNovartis151.2229.2523.98%
BMYBristol-Myers Squibb58.3414.3632.65%
Compare key indicators and discover each stock’s average analyst price target, as well as the latest recommendations by top Wall Street experts